Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Vilanterol Trifenatate

If you want to know more about the Vilanterol Trifenatate, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Vilanterol Trifenatate industry. More news about Vilanterol Trifenatate, are being released. Follow us / contact us for more Vilanterol Trifenatate information!
  • Drug Patent & Exclusivity Expiration Report - Week of July 21 2025

    Drug Patent & Exclusivity Expiration Report - Week of July 21 2025

    2025-07-21

    This week, there are 12 drugs in the patent and exclusivity list. They are: - NEURELIS INC's VALTOCO, containing active ingredient DIAZEPAM - DUCHESNAY INC's OSPHENA, containing active ingredient OSPEMIFENE - GILEAD SCIENCES INC's ZYDELIG, containing active ingredient IDELALISIB - SUN PHARMACEUTICAL INDUSTRIES LTD's WINLEVI, containing active ingredient CLASCOTERONE - SENTYNL THERAPEUTICS INC's ZOKINVY, containing active ingredient LONAFARNIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's TRELEGY ELLIPTA, containing active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE's INCRUSE ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR Read More
  • Drug Patent & Exclusivity Expiration Report - Week of May 19 2025

    Drug Patent & Exclusivity Expiration Report - Week of May 19 2025

    2025-05-19

    This week, there are 15 drugs in the patent and exclusivity list. They are: - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC's PROAIR RESPICLICK, containing active ingredient ALBUTEROL SULFATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's TRELEGY ELLIPTA, containing active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE's BREO ELLIPTA, containing active ingredient FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - AZURITY PHARMACEUTICALS INC's EDARBYCLOR, containing active ingredient AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE Read More